Metabolic dysfunction is not simply about eating too much or exercising too little — it is a complex breakdown of cellular energy sensing, hormonal signaling, and mitochondrial function. Insulin resistance, the centerpiece of metabolic syndrome, occurs when cells become unresponsive to insulin's glucose-clearing signal, leading to chronically elevated blood sugar, increased fat storage, and systemic inflammation.
Peptide therapy offers unprecedented tools to address metabolic dysfunction at the cellular level. MOTS-c — a peptide encoded in mitochondrial DNA and only discovered in 2015 — activates AMPK (the cell's master energy switch), increases insulin sensitivity, and mimics many of the benefits of exercise at the metabolic level. It represents a new frontier in metabolic medicine.
MOTS-c research shows it can increase insulin sensitivity by up to 60% in pre-diabetic models, reduce visceral fat accumulation, and improve mitochondrial biogenesis — effects comparable to exercise training achieved through a peptide. Human trials are ongoing with highly promising preliminary data.
Our metabolic health protocols combine peptide therapy with comprehensive metabolic testing (insulin, HOMA-IR, fasting glucose, metabolic rate assessment, body composition), nutritional guidance, and hormone optimization — because metabolic dysfunction and hormonal decline are deeply intertwined.